Vivani Medical (VANI · NASDAQ)

HealthcareNASDAQUSASmall

Implanting Innovation

Long-acting GLP-1 implants targeting the massive and rapidly expanding obesity treatment market.

Vivani Medical Inc

VANI: NASDAQ

1.49 USD

+18.90%

year to date

Market Cap$117.28M

Avg Volume477.25K

Price$1.49+7.19%

Pricing delayed 20 minutes Sep 4, 2026, 8:00 PM

A New Delivery Model For GLP-1 Therapies
Implants could dramatically improve adherence and outcomes compared with weekly injections.
Exposure To The Fastest Growing Market In Pharma
GLP-1 obesity drugs are projected to reach ~$139B annual market by 2030.
Platform Technology With Multiple Pipeline Opportunities
NanoPortal enables multiple long-acting drug implants across obesity, diabetes and other diseases.

Clinical Development Risk
Early-stage biotech programs face uncertain clinical outcomes and regulatory hurdles.
Funding And Cash Burn
Ongoing trials require capital; dilution risk remains for shareholders.
Competitive GLP-1 Landscape
Major pharma companies dominate obesity drugs with extensive resources.